Estrella Immunopharma Inc Share Price Today: Live Updates & Key Insights

Estrella Immunopharma Inc share price today is $1.01, up -5.45%. The stock opened at $1.022 against the previous close of $1.1, with an intraday high of $1.09 and low of $1.01.

Estrella Immunopharma Inc Share Price Chart

Estrella Immunopharma Inc

us-stock
To Invest in {{usstockname}}
us-stock

Estrella Immunopharma Inc Share Price Performance

$1.01 -0.0545(-5.45%) ESLA at 23 Mar 2026 12:55 PM Biotechnology
Lowest Today 1.01
Highest Today 1.09
Today’s Open 1.022
Prev. Close 1.1
52 Week High 3.15
52 Week Low 0.73
Day’s Range: Low 1.01 High 1.09
52-Week Range: Low 0.73 High 3.15
1 day return -
1 Week return -16.52
1 month return -15.12
3 month return -35.66
6 month return -12.93
1 year return +6.31
3 year return -90.56
5 year return -89.72
10 year return -

Estrella Immunopharma Inc Institutional Holdings

Estrella Immunopharma Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Estrella Immunopharma Inc Fundamentals

Market Cap 81.54 M

PB Ratio 4.1327

PE Ratio 0.0

Enterprise Value 44.61 M

Total Assets 3.18 M

Volume 134236

Estrella Immunopharma Inc Company Financials

Annual Revenue FY24:null 0.0M

Annual Profit FY24:null 0.0M

Annual Net worth FY24:-7311723 -7.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-4801149 -4.8M, Q2/2025:-5544878 -5.5M, Q1/2025:-2104311 -2.1M, Q3/2024:-3376737 -3.4M, Q2/2024:-3951072 -4.0M

About Estrella Immunopharma Inc & investment objective

Company Information Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Dr. Cheng Liu Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Estrella Immunopharma Inc FAQs

What is the share price of Estrella Immunopharma Inc today?

The current share price of Estrella Immunopharma Inc is $1.01.

Can I buy Estrella Immunopharma Inc shares in India?

Yes, Indian investors can buy Estrella Immunopharma Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Estrella Immunopharma Inc shares in India?

You can easily invest in Estrella Immunopharma Inc shares from India by:

Can I buy fractional shares of Estrella Immunopharma Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Estrella Immunopharma Inc?

Estrella Immunopharma Inc has a market cap of $81.54 M.

In which sector does Estrella Immunopharma Inc belong?

Estrella Immunopharma Inc operates in the Biotechnology sector.

What documents are required to invest in Estrella Immunopharma Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Estrella Immunopharma Inc?

The PE ratio of Estrella Immunopharma Inc is N/A and the PB ratio is 4.13.